Hematology

TTP

Questions discussed in this category

Would you consider caplacizumab in a pregnant patient with iTTP?

Caplacizumab is not FDA approved in pregnant patients, but has been used safely in isolated case reports.

1 Answer available

How do you approach a patient with chronic low ADAMTS13 activity and low level of inhibitor without signs of thrombocytopenia or hemolysis?

ADAMTS13 level <5% Inhibitor level <1

1 Answer available

How do you explain TTP to patients?

1 Answer available

Papers discussed in this category

Blood, 2018 Sep 10

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.

British journal of haematology, 2021 Sep 29

First use of the anti-VWF nanobody caplacizumab to treat iTTP in pregnancy.

British journal of haematology, 2023 May 24

A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura.

British journal of haematology, 2024 Jan 02

Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab.

Cureus, 2023 Oct 16

An Interesting Case of Refractory Thrombotic Thrombocytopenic Purpura in the First Trimester of a Twin Pregnancy.

Related Topics in Hematology